Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTJP4SM)

• DTT Name: Bacterial Penicillin binding protein (Bact PBP)
• Gene Name: NO-GeName
• DTT Type: Successful target; [1]
• Related Disease:
  Acute bronchitis [ICD-11: CA42]
  Anaerobic bacterial infection [ICD-11: 1A00-1A09]
  Bacterial infection [ICD-11: 1A00-1C4Z]
  Bronchitis [ICD-11: CA20]
  Glanders [ICD-11: 1B92]
  Gram-positive bacterial infection [ICD-11: 1B74-1F40]
  Mature B-cell lymphoma [ICD-11: 2A85]
  Myelodysplastic syndrome [ICD-11: 2A37]
  Respiratory infection [ICD-11: CA07-CA4Z]
  Rheumatoid arthritis [ICD-11: FA20]
  Sepsis [ICD-11: 1G40-1G41]
  Urinary tract infection [ICD-11: GC08]
• UniProt ID: NOUNIPROTAC
• TTD ID: T34743
• Function: Cell wall formation.

Molecular Interaction Atlas (MIA) of This DTT

57 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ampicillin	DMHWE7P	Bacterial infection	1A00-1C4Z	Approved	[2]
Azlocillin	DMIR5QP	Pseudomonas infection	1B92	Approved	[3]
Bacampicillin	DMP54C7	Bacterial infection	1A00-1C4Z	Approved	[4]
Balofloxacin	DMPWNDB	Gram-positive bacterial infection	1B74-1G40	Approved	[5]
Carbenicillin	DMLEDNK	Infection of the upper and lower urinary tract	GC08	Approved	[6]
Carbenicillin Indanyl Sodium	DME2XG3	Bacterial infection	1A00-1C4Z	Approved	[7]
Cefacetrile	DMRSZA5	Bacterial infection	1A00-1C4Z	Approved	[8]
Cefaclor	DMJXDGC	Bacterial infection	1A00-1C4Z	Approved	[9]
Cefadroxil	DMMC345	Bacterial infection	1A00-1C4Z	Approved	[10]
Cefamandole	DMNEXZF	Microorganisms infection	1A00-1A09	Approved	[11]
Cefazolin	DMPDYFR	Bacterial infection	1A00-1C4Z	Approved	[12]
Cefdinir	DMJ7A0H	Bacterial infection	1A00-1C4Z	Approved	[13]
Cefditoren	DMSUVM1	Bacterial infection	1A00-1C4Z	Approved	[14]
Cefixime	DMY60I8	Bacterial infection	1A00-1C4Z	Approved	[15]
Cefonicid	DMTX2BH	Bacterial infection	1A00-1C4Z	Approved	[16]
Cefoperazone	DM53PV8	Bacterial infection	1A00-1C4Z	Approved	[17]
Ceforanide	DMSQVD6	Bacterial infection	1A00-1C4Z	Approved	[18]
Cefotetan	DM07TX3	Bacterial infection	1A00-1C4Z	Approved	[19]
Cefoxitin	DMYTXVR	Bacterial infection	1A00-1C4Z	Approved	[20]
Cefpiramide	DMZ2WL4	Bacterial infection	1A00-1C4Z	Approved	[4]
Cefpodoxime	DMJUNY5	Bacterial infection	1A00-1C4Z	Approved	[21]
Cefprozil	DM7DSYP	Bacterial infection	1A00-1C4Z	Approved	[22]
Cefradine	DMUNSWV	Bacterial infection	1A00-1C4Z	Approved	[20]
Ceftazidime	DM41GRA	Bacterial infection	1A00-1C4Z	Approved	[23]
Ceftibuten	DMWV2AG	Chronic bronchitis	CA20.1	Approved	[24]
Ceftizoxime	DM3VOGS	Bacterial infection	1A00-1C4Z	Approved	[1]
Ceftriaxone	DMCEW64	Bacterial infection	1A00-1C4Z	Approved	[25]
Cefuroxime	DMSIMD8	Acute bronchitis	CA42	Approved	[26]
Cephalexin	DMD5JU8	Bacterial infection	1A00-1C4Z	Approved	[27]
Cephaloglycin	DMYZITL	Bacterial infection	1A00-1C4Z	Approved	[25]
Cephalothin sodium	DM51Z9E	Bacterial infection	1A00-1C4Z	Approved	[25]
Cephapirin	DMV2JNY	Sepsis	1G40-1G41	Approved	[28]
Ciprofloxacin XR	DM2NLS9	Bacterial infection	1A00-1C4Z	Approved	[5]
Clofarabine	DMCVJ86	Acute lymphoblastic leukaemia	2A85	Approved	[29]
Cloxacillin	DMUTL7O	Bacterial infection	1A00-1C4Z	Approved	[30]
Cyclacillin	DMHSJB4	Bacterial infection	1A00-1C4Z	Approved	[4]
Dicloxacillin	DM8EU0Z	Bacterial infection	1A00-1C4Z	Approved	[31]
Ertapenem	DM4S3O8	Bacterial infection	1A00-1C4Z	Approved	[1]
Flucloxacillin	DMNUWST	Bacterial infection	1A00-1C4Z	Approved	[31]
Hetacillin	DMPXITB	Bacterial infection	1A00-1C4Z	Approved	[32]
Loracarbef	DM4L8H3	Bacterial infection	1A00-1C4Z	Approved	[21]
Meropenem	DM62UHC	Bacterial infection	1A00-1C4Z	Approved	[25]
Meticillin	DMIKHN0	Bacterial infection	1A00-1C4Z	Approved	[33]
Nafcillin	DMN9RPO	Arthritis	FA20	Approved	[34]
Oxacillin	DMTAFY4	Bacterial infection	1A00-1C4Z	Approved	[35]
Penicillin	DMNMHBV	Bacterial infection	1A00-1C4Z	Approved	[36]
Penicillin G Benzathine	DM49VEW	Bacterial infection	1A00-1C4Z	Approved	[36]
Penicillin G Procaine	DMU4JLB	Bacterial infection	1A00-1C4Z	Approved	[36]
Penicillin G Sodium	DMY18XK	Bacterial infection	1A00-1C4Z	Approved	[36]
Penicillin V	DMKVOYF	Bacterial infection	1A00-1C4Z	Approved	[37]
Penicillin V Potassium	DM8LX76	Bacterial infection	1A00-1C4Z	Approved	[25]
Piperacillin	DMTBKF3	Bacterial infection	1A00-1C4Z	Approved	[38]
Pivampicillin	DMX8CVY	Bacterial infection	1A00-1C4Z	Approved	[4]
Pivmecillinam	DMDU0BV	Urinary tract infection	GC08	Approved	[39]
Tebipenem pivoxil	DMQ5S6C	Respiratory tract infection	CA45	Approved	[40]
Ticarcillin	DM4ME02	Bacterial infection	1A00-1C4Z	Approved	[41]
Ceftolozane sulfate	DMYGEH7	Respiratory tract infection	CA45	Phase 4	[42]

8 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cefluprenam	DMLWIU4	Bacterial infection	1A00-1C4Z	Phase 3	[43]
Ceftobiprole	DMM76GL	Community-acquired pneumonia	CA40.Z	Phase 3	[44]
Ceftobiprole medocaril	DMWLF2X	Skin and skin-structure infection	1F28-1G0Z	Phase 3	[45]
Sulopenem	DMMD856	Urinary tract infection	GC08	Phase 3	[46]
BOS-228	DMZ70GE	Bacterial infection	1A00-1C4Z	Phase 2	[47]
Lenapenem hydrochloride hydrate	DMZKBMG	Bacterial infection	1A00-1C4Z	Phase 2	[48]
BAL-30072	DM5KU30	Bacterial infection	1A00-1C4Z	Phase 1	[49]
DZ-2640	DMS1NC8	Bacterial infection	1A00-1C4Z	Phase 1	[50]

14 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CEFCANEL DALOXATE HYDROCHLORIDE	DMANMXZ	Bacterial infection	1A00-1C4Z	Discontinued in Phase 3	[51]
CEFETECOL	DMEMUQP	Bacterial infection	1A00-1C4Z	Discontinued in Phase 3	[52]
Sanfetrinem	DM3KC81	Bacterial infection	1A00-1C4Z	Discontinued in Phase 3	[53]
KP-736	DMM1SLF	Bacterial infection	1A00-1C4Z	Discontinued in Phase 2	[54]
PA-1806	DM4ZNKX	Bacterial infection	1A00-1C4Z	Discontinued in Phase 2	[55]
Tomopenem	DM1YXPL	Bacterial infection	1A00-1C4Z	Discontinued in Phase 2	[56]
BRL-44154	DMIX9O0	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[57]
Cefdaloxime pentexil tosilate	DMJVZ9O	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[58]
CEFTRAZONAL BOPENTIL	DMO075K	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[59]
DU-6681	DM9S51Q	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[60]
ER-35786	DM3LKAR	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[61]
FK-041	DMVL5RC	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[62]
MC-02,479	DMRIK2Y	Bacterial infection	1A00-1C4Z	Discontinued in Phase 1	[63]
BK-218	DM9IQR6	Bacterial infection	1A00-1C4Z	Terminated	[64]

5 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Anthramycin	DMNEGHJ	Discovery agent	N.A.	Investigative	[65]
Cis-[PtCl(NH3)2(N7-acyclovir)]+	DMV3RYK	Discovery agent	N.A.	Investigative	[66]
Naphthyridinomycin	DMTWEQP	Discovery agent	N.A.	Investigative	[67]
RO 244383	DM3FYUM	Discovery agent	N.A.	Investigative	[68]
Sanfetrinem cilexetil	DMTRMX8	Discovery agent	N.A.	Investigative	[53]

References

• [1] Role of penicillin-binding protein 2 (PBP2) in the antibiotic susceptibility and cell wall cross-linking of Staphylococcus aureus: evidence for the cooperative functioning of PBP2, PBP4, and PBP2A. JBacteriol. 2005 Mar;187(5):1815-24.
• [2] Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. Antimicrob Agents Chemother. 2002 May;46(5):1273-80.
• [3] Reactivation of peptidoglycan synthesis in ether-permeabilized Escherichia coli after inhibition by beta-lactam antibiotics. Antimicrob Agents Chemother. 1989 Dec;33(12):2101-8.
• [4] Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
• [5] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [6] Resistance of Pseudomonas aeruginosa to cefsulodin: modification of penicillin-binding protein 3 and mapping of its chromosomal gene. J Antimicrob Chemother. 1990 Apr;25(4):513-23.
• [7] Carbenicillin resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1982 Aug;22(2):255-61.
• [8] Single dose 1 g ceftriaxone for urogenital and pharyngeal infection caused by Neisseria gonorrhoeae. Int J Urol. 2008 Sep;15(9):837-42.
• [9] Antibacterial activity of oral cephems against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory. Jpn J Antibiot. 2004 Dec;57(6):465-74.
• [10] Penicillin-binding protein sensitive to cephalexin in sporulation of Bacillus cereus. Microbiol Res. 1997 Sep;152(3):227-32.
• [11] The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. J Infect Dis. 1998 Jan;177(1):146-54.
• [12] Bacteriological characteristics of Staphylococcus aureus isolates from humans and bulk milk. J Dairy Sci. 2008 Feb;91(2):564-9.
• [13] Decreased affinity of mosaic-structure recombinant penicillin-binding protein 2 for oral cephalosporins in Neisseria gonorrhoeae. J Antimicrob Chemother. 2007 Jul;60(1):54-60.
• [14] Crystal structure of cefditoren complexed with Streptococcus pneumoniae penicillin-binding protein 2X: structural basis for its high antimicrobial ... Antimicrob Agents Chemother. 2007 Nov;51(11):3902-7.
• [15] Genetics of chromosomally mediated intermediate resistance to ceftriaxone and cefixime in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2009 Sep;53(9):3744-51.
• [16] Affinity of cefonicid, a long-acting cephalosporin, for the penicillin-binding proteins of Escherichia coli K-12. J Antibiot (Tokyo). 1984 May;37(5):572-6.
• [17] Clinical relevance of antibiotic-induced endotoxin release in patients undergoing hepatic resection. World J Surg. 1999 Jan;23(1):75-9.
• [18] The pharmacokinetics of the interstitial space in humans. BMC Clin Pharmacol. 2003 Jul 30;3:3.
• [19] In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect. 2007 Jun;13 Suppl 2:17-24.
• [20] Staphylococcus aureus PBP4 is essential for beta-lactam resistance in community-acquired methicillin-resistant strains. Antimicrob Agents Chemother. 2008 Nov;52(11):3955-66.
• [21] Amino acid substitutions in mosaic penicillin-binding protein 2 associated with reduced susceptibility to cefixime in clinical isolates of Neisseri... Antimicrob Agents Chemother. 2006 Nov;50(11):3638-45.
• [22] Microbiology and antimicrobial management of sinusitis. J Laryngol Otol. 2005 Apr;119(4):251-8.
• [23] New and emerging treatment of Staphylococcus aureus infections in the hospital setting. Clin Microbiol Infect. 2008 Apr;14 Suppl 3:32-41.
• [24] Neisseria gonorrhoeae and emerging resistance to extended spectrum cephalosporins. Curr Opin Infect Dis. 2009 Feb;22(1):87-91.
• [25] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [26] Cefuroxime resistance in non-beta-lactamase Haemophilus influenzae is linked to mutations in ftsI. J Antimicrob Chemother. 2003 Mar;51(3):523-30.
• [27] Relationship between penicillin-binding protein patterns and beta-lactamases in clinical isolates of Bacteroides fragilis with different susceptibility to beta-lactam antibiotics. J Med Microbiol. 2004 Mar;53(Pt 3):213-21.
• [28] The formation of functional penicillin-binding proteins. J Biol Chem. 1975 Aug 25;250(16):6578-85.
• [29] Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
• [30] Development of a receptor-based microplate assay for the detection of beta-lactam antibiotics in different food matrices. Anal Chim Acta. 2007 Mar 14;586(1-2):296-303.
• [31] Mechanisms of resistance to beta-lactam antibiotics in Staphylococcus aureus. Scand J Infect Dis Suppl. 1984;42:64-71.
• [32] JBioWH: an open-source Java framework for bioinformatics data integration.Database (Oxford).2013 Jul 11;2013:bat051.
• [33] A link in transcription between the native pbpB and the acquired mecA gene in a strain of Staphylococcus aureus. Microbiology. 2006 Sep;152(Pt 9):2549-58.
• [34] Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J Infect Dis. 1990 Sep;162(3):705-10.
• [35] Novel anion liposome-encapsulated antisense oligonucleotide restores susceptibility of methicillin-resistant Staphylococcus aureus and rescues mice... Antimicrob Agents Chemother. 2009 Jul;53(7):2871-8.
• [36] Bacterial Resistance to Penicillin G by Decreased Affinity of Penicillin-Binding Proteins: A Mathematical Model
• [37] Localization of penicillin-binding proteins to the splitting system of Staphylococcus aureus septa by using a mercury-penicillin V derivative. J Bacteriol. 1995 Jul;177(13):3631-40.
• [38] In vitro antienterococcal activity explains associations between exposures to antimicrobial agents and risk of colonization by multiresistant enter... J Infect Dis. 2004 Dec 15;190(12):2162-6.
• [39] Association between antimicrobial consumption and resistance in Escherichia coli. Antimicrob Agents Chemother. 2009 Mar;53(3):912-7.
• [40] In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria. Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02181-18.
• [41] Activities of antibiotics against methicillin-resistant Staphylococcus aureus with particular reference to synergetic effect between ticarcillin and fosfomycin on penicillinase non-producing methicillin-resistant S. aureus. Jpn J Antibiot. 1993 Jun;46(6):421-7.
• [42] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [43] Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991 Nov;35(11):2312-7.
• [44] Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and ... Antimicrob Agents Chemother. 2007 Jul;51(7):2621-4.
• [45] Ceftobiprole medocaril for the treatment of community-acquired pneumonia. Expert Opin Pharmacother. 2018 Sep;19(13):1503-1509.
• [46] In vitro antibacterial activity of a new parenteral penem, sulopenem. Jpn J Antibiot. 1996 Apr;49(4):324-37.
• [47] Clinical pipeline report, company report or official report of Boston Pharmaceuticals.
• [48] Affinities of BO-2727 for bacterial penicillin-binding proteins and morphological change of gram-negative rods. J Antibiot (Tokyo). 1997 Feb;50(2):139-42.
• [49] In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant gram-negative bacilli. Antimicrob Agents Chemother. 2010 Jun;54(6):2291-302.
• [50] In vitro activity of DU-6681a, an active form of the new oral carbapenem compound DZ-2640, in comparison with that of R-95867, faropenem and oral cephalosporins. J Antimicrob Chemother. 2000 Jul;46(1):101-8.
• [51] Pharmacokinetics of oral cefcanel daloxate hydrochloride in healthy volunteers and patients with various degrees of impaired renal function. J Antimicrob Chemother. 1994 Feb;33(2):281-8.
• [52] Antibacterial activities in vitro and in vivo and pharmacokinetics of cefquinome (HR 111V), a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1991 Jan;35(1):14-9.
• [53] Entry of Sanfetrinem into Human Polymorphonuclear Granulocytes and Its Cell-Associated Activity against Intracellular, Penicillin-Resistant Streptococcus pneumoniae
• [54] In vitro antibacterial activity of KP-736, a new cephem antibiotic. Antimicrob Agents Chemother. 1991 Jan;35(1):104-10.
• [55] Antibacterial activity of BMS-180680, a new catechol-containing monobactam. Antimicrob Agents Chemother. 1997 May;41(5):1010-6.
• [56] Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.Antimicrob Agents Chemother.2009 Mar;53(3):1238-41.
• [57] Can beta-lactams be re-engineered to beat MRSA . Clinical Microbiology and Infection Volume 12, Issue Supplement s2, pages 11-16, April 2006.
• [58] Activity of cefpodoxime and other oral beta-lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter. 2006 Mar;19(1):39-44.
• [59] Comparative in vitro activity of Ro 40-6890, Ro 41-3399, and other antimicrobial agents against anaerobic bacteria. Eur J Clin Microbiol Infect Dis. 1992 Oct;11(10):946-9.
• [60] Pharmacokinetics and Safety of Ascending Single Doses of DZ-2640, a New Oral Carbapenem Antibiotic, Administered to Healthy Japanese Subjects. Antimicrob Agents Chemother. 2000 March; 44(3): 578-582.
• [61] In vitro and in vivo antibacterial activities of ER-35786, a new antipseudomonal carbapenem. Antimicrob Agents Chemother. 1997 Feb;41(2):298-307.
• [62] In vitro antibacterial activity of FK041, a new orally active cephalosporin. J Antibiot (Tokyo). 1999 Jul;52(7):649-59.
• [63] RWJ-54428 (MC-02,479), a new cephalosporin with high affinity for penicillin-binding proteins, including PBP 2a, and stability to staphylococcal be... Antimicrob Agents Chemother. 2003 Feb;47(2):658-64.
• [64] In vitro investigation of BK-218, a new oral and parenteral cephalosporin. Antimicrob Agents Chemother. 1990 Feb;34(2):349-54.
• [65] Crystal structure of a covalent DNA-drug adduct: anthramycin bound to C-C-A-A-C-G-T-T-G-G and a molecular explanation of specificity. Biochemistry. 1994 Nov 22;33(46):13593-610.
• [66] DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+. Mol Pharmacol. 1998 May;53(5):846-55.
• [67] Naphthyridinomycin-DNA adducts: a molecular modeling study. J Antibiot (Tokyo). 1991 Aug;44(8):885-94.
• [68] Mechanisms of resistance to cephalosporin antibiotics.Drugs.1987;34 Suppl 2:64-88.